Posted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate to severe plaque psoriasis.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the United Kingdom’s NICE has published positive guidance for Tremfya (guselkumab), following its positive Final Appraisal Determination delivered on 2 May 2018. This means that adults with moderate to severe plaque psoriasis will now have access to guselkumab through the National Health Service in England and Wales.
Additionally, on 17 May 2018, Germany’s drug reimbursement body, The Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) published its decision stating that guselkumab offered “substantial additional therapeutic benefits” compared to treatment with comparators for all patient populations assessed. This is the first time a biologic treatment for psoriasis has been awarded this level of benefit.
